AYR Wellness Reports Third Quarter 2024 Results
AYR Wellness reported Q3 2024 financial results showing revenue of $114.3M, down 0.1% year-over-year and 2.6% quarter-over-quarter. The company faced macroeconomic pressures and increased competition, though this was partially offset by adult-use sales launch in Ohio. Despite lower revenue, Adjusted EBITDA improved to $26.1M with a 22.9% margin. The company expanded operations in Ohio, received conditional approval in Virginia, and entered Connecticut market. Management expects Q4 revenue and Adjusted EBITDA to remain flat compared to Q3, while maintaining positive GAAP cash flow forecast for 2024.
AYR Wellness ha riportato i risultati finanziari del terzo trimestre del 2024, evidenziando un fatturato di 114,3 milioni di dollari, in calo dello 0,1% rispetto all'anno precedente e del 2,6% rispetto al trimestre precedente. L'azienda ha affrontato pressioni macroeconomiche e una maggiore concorrenza, anche se questo è stato parzialmente compensato dal lancio delle vendite per uso adulto in Ohio. Nonostante il fatturato più basso, l'EBITDA Rettificato è migliorato a 26,1 milioni di dollari con un margine del 22,9%. L'azienda ha ampliato le sue operazioni in Ohio, ha ricevuto approvazione condizionata in Virginia e ha fatto il suo ingresso nel mercato del Connecticut. La direzione si aspetta che il fatturato del quarto trimestre e l'EBITDA rettificato rimangano stabili rispetto al terzo trimestre, mantenendo una previsione di flusso di cassa GAAP positivo per il 2024.
AYR Wellness reportó resultados financieros del tercer trimestre de 2024, mostrando ingresos de 114,3 millones de dólares, una disminución del 0,1% año sobre año y del 2,6% trimestre a trimestre. La compañía enfrentó presiones macroeconómicas y una mayor competencia, aunque esto fue parcialmente compensado por el lanzamiento de ventas para uso adulto en Ohio. A pesar de la caída en los ingresos, el EBITDA Ajustado mejoró a 26,1 millones de dólares con un margen del 22,9%. La empresa amplió sus operaciones en Ohio, recibió aprobación condicional en Virginia y entró en el mercado de Connecticut. La dirección espera que los ingresos y el EBITDA ajustado del cuarto trimestre se mantengan estables en comparación con el tercer trimestre, mientras mantiene una previsión de flujo de efectivo GAAP positivo para 2024.
AYR 웰니스는 2024년 3분기 재무 결과를 보고하며 매출이 1억 1,430만 달러로 작년 대비 0.1%, 전분기 대비 2.6% 감소했다고 밝혔다. 회사는 거시 경제적 압박과 증가하는 경쟁에 직면했으나, 이는 부분적으로 오하이오에서 성인 사용을 위한 판매 시작으로 상쇄되었다. 매출은 감소했지만, 조정 EBITDA는 2,610만 달러로 개선되었고, 이익률은 22.9%에 달했다. 회사는 오하이오에서 운영을 확대하고, 버지니아에서 조건부 승인을 받았으며, 코네티컷 시장에 진입했다. 경영진은 4분기 매출과 조정 EBITDA가 3분기 대비 변동이 없을 것으로 예상하며, 2024년에는 지속적으로 긍정적인 GAAP 현금 흐름 예측을 유지하고 있다.
AYR Wellness a publié les résultats financiers du troisième trimestre 2024, montrant un chiffre d'affaires de 114,3 millions de dollars, soit une baisse de 0,1 % par rapport à l'année précédente et de 2,6 % par rapport au trimestre précédent. L'entreprise a dû faire face à des pressions macroéconomiques et à une concurrence accrue, bien que cela ait été partiellement compensé par le lancement des ventes pour usage adulte dans l'Ohio. Malgré une baisse du chiffre d'affaires, l'EBITDA ajusté s'est amélioré à 26,1 millions de dollars avec une marge de 22,9 %. L'entreprise a élargi ses opérations dans l'Ohio, a obtenu une approbation conditionnelle en Virginie et est entrée sur le marché du Connecticut. La direction s'attend à ce que le chiffre d'affaires et l'EBITDA ajusté du quatrième trimestre restent stables par rapport au troisième trimestre, tout en maintenant une prévision de flux de trésorerie GAAP positif pour 2024.
AYR Wellness hat die finanziellen Ergebnisse für das 3. Quartal 2024 veröffentlicht und einen Umsatz von 114,3 Millionen US-Dollar gemeldet, was einem Rückgang von 0,1 % im Jahresvergleich und 2,6 % im Quartalsvergleich entspricht. Das Unternehmen sah sich makroökonomischen Druck und steigender Konkurrenz gegenüber, was jedoch teilweise durch den Start des Verkaufs für Erwachsene in Ohio ausgeglichen wurde. Ungeachtet des rückläufigen Umsatzes verbesserte sich das bereinigte EBITDA auf 26,1 Millionen US-Dollar mit einer Marge von 22,9 %. Das Unternehmen erweiterte seine Aktivitäten in Ohio, erhielt eine bedingte Genehmigung in Virginia und trat in den Markt von Connecticut ein. Das Management rechnet damit, dass der Umsatz und das bereinigte EBITDA im 4. Quartal im Vergleich zum 3. Quartal konstant bleiben, während eine positive GAAP-Cashflow-Prognose für 2024 aufrechterhalten wird.
- Adjusted EBITDA margin improved to 22.9%, up 100bps quarter-over-quarter
- Received conditional approval for Virginia pharmaceutical processor license
- Successfully launched adult-use sales in Ohio
- Expanded retail presence with new stores in Illinois, Florida, and Connecticut
- Revenue declined 2.6% quarter-over-quarter to $114.3M
- Gross profit decreased 10.6% year-over-year to $43.0M
- Operating loss widened to $17.4M from $1.4M year-over-year
- Failed Amendment 3 referendum in Florida impacts growth potential
MIAMI, Nov. 13, 2024 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, is reporting financial results for the third quarter ended September 30, 2024. Unless otherwise noted, all results are presented in U.S. dollars.
Steven M. Cohen, Interim CEO of AYR, said, “Our third quarter performance reflected ongoing macroeconomic pressure to the consumer wallet and increased competition in select markets, which affected revenue and offset the growth from the launch of adult-use sales in Ohio. However, our team adapted to drive gross margin expansion and operating efficiencies, improving our Adjusted EBITDA despite the lower revenue.
"Notwithstanding the ongoing leadership transition, we remain focused on strengthening execution and are committed to positioning AYR for sustained growth and profitability. Particularly, in 2025, we plan to expand our presence in Ohio, develop an initial footprint in Virginia, and improve our vertical operations in Florida. Although we are disappointed by the result of the Amendment 3 referendum last week in Florida, we continue to maintain strong share in the state’s medical market and see potential for revenue growth as our new indoor cultivation facility comes online next year, which will fill a crucial gap by supplying high-quality indoor flower to our stores. We are well-positioned to navigate the near-term environment as we focus on improving execution in our key markets.”
Third Quarter Financial Summary
| Q3 2023 | Q2 2024 | Q3 2024 | % Change Q3/Q3 | % Change Q3/Q2 | |||||||||
| Revenue | - | - | |||||||||||
| Gross Profit | - | - | |||||||||||
| Adjusted Gross Profit1 | - | - | |||||||||||
| Operating Loss | NA | NA | |||||||||||
| Adjusted EBITDA1 | - | ||||||||||||
| Adjusted EBITDA Margin1 | 22.9 % | -200bps | 100bps | ||||||||||
1 Adjusted EBITDA, Adjusted Gross Profit and Adjusted EBITDA Margin are non-GAAP measures, and accordingly are not standardized measures and may not be comparable to similar measures used by other companies. See Definition and Reconciliation of Non-GAAP Measures below. For a reconciliation of Operating Loss to Adjusted EBITDA as well as Gross Profit to Adjusted Gross Profit, see the reconciliation tables appended to this release.
Third Quarter and Recent Highlights
- Received conditional approval to serve as a pharmaceutical processor by the Virginia Cannabis Control Authority with exclusive rights to service Health Service Area 1, one of five service regions in the state of Virginia.2
- Launched adult-use sales in Ohio with three affiliated AYR stores and wholesale operations. The Company has also started the process of building out five new dispensaries in Ohio that are expected to open in the first half of 2025.
- In November 2024, the New York Cannabis Control Board voted to approve the application for Amethyst Health, LLC (“Amethyst Health”) for registration as a “Registered Organization,” which would conditionally allow the company to commence medical marijuana operations in the state. AYR is an operational partner and minority equity holder in Amethyst Health.
- Entered the Connecticut market with the opening of AYR Cannabis Manchester.
- Opened four retail stores in total during the quarter, including the Company’s fourth Illinois retail store in July, and the Company’s 65th and 66th stores in Florida.
Board & Management Changes
- In July 2024, Louis Karger was appointed Chairman of the Company’s board of directors (the “Board”) following the resignation of prior Executive Chairman, Jonathan Sandelman.
- In September 2024, the Company appointed Steven M. Cohen as interim Chief Executive Officer, replacing David Goubert, who stepped down as CEO and President. The Board is currently conducting a search for a permanent CEO and has retained True Search, a global recruiting firm, to lead the search.
- In October 2024, Jamie Mendola and Julie Winter were promoted to interim Co-Chief Revenue Officers of the Company, after having previously held the positions of Regional Senior Vice Presidents. George Denardo’s role as Chief Operating Officer was expanded to provide greater oversight of marketing and greater coordination with the interim Co-Chief Revenue Officers.
Financing and Capital Structure
The Company deployed
As of September 30, 2024, the Company had approximately 116.2 million fully diluted shares outstanding based on a treasury method calculation as of that date (excluding 23 million warrants expiring in February 2026 with an exercise price of
Outlook
For the fourth quarter, the Company expects revenue and Adjusted EBITDA to be essentially flat compared to the third quarter of 2024. AYR also continues to expect positive GAAP cash flow from operations for calendar 2024.
Conference Call
AYR management will host a conference call today, followed by a question-and-answer period.
Date: Wednesday, November 13, 2024
Time: 8:30 a.m. ET
Toll-free dial-in number: (844) 763-8274
International dial-in number: (647) 484-8814
Webcast: Link
Please dial into the conference call 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at ir@ayrwellness.com.
The conference will be broadcast live and available for replay here.
A telephonic replay of the conference call will also be available for one month until end of day Friday, December 13, 2024.
Toll-free replay number: (855) 669-9658
International replay number: (412) 317-0088
Replay ID: 8552657
Financial Statements
Certain financial information and analysis reported in this news release is extracted from AYR’s Consolidated Financial Statements and MD&A for the quarter ended September 30, 2024. AYR files its financial statements and MD&A on SEDAR+ and with the SEC. All financial information contained in this news release is qualified in its entirety by reference to such financial statements and MD&A.
Definition and Reconciliation of Non-GAAP Measures
The Company reports certain non-GAAP measures that are used to evaluate the performance of its businesses and the performance of their respective segments, as well as to manage their capital structures. As non-GAAP measures generally do not have a standardized meaning, they may not be comparable to similar measures presented by other issuers. Securities regulators require such measures to be clearly defined and reconciled with their most comparable GAAP measures.
Rather, these are provided as additional information to complement those GAAP measures by providing further understanding of the results of the operations of the Company from management’s perspective. Accordingly, these measures should not be considered in isolation, nor as a substitute for analysis of the Company’s financial information reported under GAAP. Non-GAAP measures used to analyze the performance of the Company’s businesses include “Adjusted EBITDA”, “Adjusted EBITDA Margin” and “Adjusted Gross Profit.”
The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performances and may be useful to investors because they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making. These financial measures are intended to provide investors with supplemental measures of the Company’s operating performances and thus highlight trends in the Company’s core businesses that may not otherwise be apparent when solely relying on the GAAP measures.
Adjusted EBITDA – Non-GAAP Financial Measure
“Adjusted EBITDA” represents (loss) income from continuing operations, as reported under GAAP, before interest and tax, adjusted to exclude non-core costs, other non-cash items, including depreciation and amortization and further adjusted to remove non-cash stock-based compensation, impairment expense, the incremental costs to acquire cannabis inventory in a business combination (when applicable; none of which was incurred for any of the periods presented), acquisition and transaction related costs, and start-up costs. Adjusted EBITDA should not be interpreted as an alternative to net (loss) income and cash flows from operations as determined in accordance with GAAP or as measure of liquidity.
Adjusted Gross Profit – Non-GAAP Financial Measure
“Adjusted Gross Profit” represents gross profit, as reported under GAAP, adjusted to exclude the incremental costs to acquire cannabis inventory in a business combination (when applicable; none of which was incurred for any of the periods presented), interest, depreciation and amortization, start-up costs and other non-core costs.
A reconciliation of how Ayr calculates Adjusted EBITDA and Adjusted Gross Profit is provided in the tables appended below. Additional reconciliations of Adjusted EBITDA, Adjusted Gross Profit and other disclosures concerning non-GAAP measures are provided in our MD&A for the three months ended September 30, 2024.
Forward-Looking Statements
Certain statements in this MD&A are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, those statements relating to the Company, its operating subsidiaries, their respective business, and its financial capacity and availability of capital and other statements that are not historical facts. These statements are based upon certain material factors, assumptions, and analyses that were applied in drawing a conclusion or making a forecast or projection, including experience of the Company, as applicable, and perception of historical trends, current conditions, and expected future developments, as well as other factors that are believed to be reasonable in the circumstances. Forward-looking statements are provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies, and outlook of the Company. Forward-looking statements are often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “expect”, “target”, “continue”, “forecast”, “design”, “goal” or negative versions thereof and other similar expressions. These statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.
Forward-looking estimates and assumptions involve known and unknown risks and uncertainties that may cause actual results to differ materially. While Ayr believes there is a reasonable basis for these assumptions, no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. In particular, this news release contains forward-looking statements pertaining to, but not limited to, the following: operational and financial expectations for the 2024 financial year, including Adjusted EBITDA and future cash flow expectations; and the Company’s business plan.
Although the forward-looking statements contained in this news release are based upon assumptions which management of the Company believes to be reasonable, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. With respect to forward-looking statements contained in this news release, the Company has made assumptions regarding, but not limited to: the Company’s ability to execute on its business plan; general economic and industry trends; operating assumptions relating to the Company’s operations; demand for the Company’s products and services; and the other assumptions set forth in the Company’s most recent annual information form available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
The Company’s actual results could differ materially from those anticipated in the forward-looking statements, as a result of numerous known and unknown risks and uncertainties and other factors including, but not limited to: changes in demand for the Company’s products and services; general economic, political, market and business conditions, including fluctuations in interest rates, foreign exchange rates, stock market volatility; reliance on key management personnel; risks related to competition within the Company’s industry and relating to technological advances; litigation risks; cyber-security risks; risks of health epidemics, pandemics and similar outbreaks; and the other risks set forth in the Company’s most recent annual information form and MD&A for the quarter ended September 30, 2024 available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
The Company’s actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits the Company will derive therefrom. Readers are therefore cautioned that the foregoing lists of important factors are not exhaustive, and they should not unduly rely on the forward-looking statements included in this news release. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement. AYR has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Assumptions and Risks
Forward-looking information in this release is subject to the assumptions and risks as described in our MD&A for the quarter ended September 30, 2024.
Additional Information
For more information about the Company’s Q3 2024 operations and outlook, please view AYR’s corporate presentation posted in the Investors section of the Company’s website at www.ayrwellness.com.
About AYR Wellness Inc.
AYR Wellness is a vertically integrated, U.S. multi-state cannabis business. The Company operates simultaneously as a retailer with 90+ licensed dispensaries and a house of cannabis CPG brands.
AYR is committed to delivering high-quality cannabis products to its patients and customers while acting as a Force for Good for its team members and the communities that the Company serves. For more information, please visit www.ayrwellness.com.
Company/Media Contact:
Robert Vanisko
VP, Public Engagement
T: (786) 885-0397
Email: comms@ayrwellness.com
Investor Relations Contact:
Sean Mansouri, CFA
Elevate IR
T: (786) 885-0397
Email: ir@ayrwellness.com
2 Several lawsuits have been filed seeking to overturn the award of this conditional approval. These legal actions are in preliminary stages, and at present, the Company intends to proceed with its planned expansion into Virginia.
| Ayr Wellness Inc. Unaudited Interim Condensed Consolidated Balance Sheets (Expressed in United States Dollars, in thousands, except share amounts) | ||||||||
| As of | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current | ||||||||
| Cash, cash equivalents and restricted cash | $ | 50,578 | $ | 50,766 | ||||
| Accounts receivable, net | 11,575 | 13,491 | ||||||
| Inventory | 119,551 | 106,363 | ||||||
| Prepaid expenses, deposits, and other current assets | 6,152 | 22,600 | ||||||
| Total Current Assets | 187,856 | 193,220 | ||||||
| Non-current | ||||||||
| Property, plant, and equipment, net | 294,210 | 310,615 | ||||||
| Intangible assets, net | 645,009 | 687,988 | ||||||
| Right-of-use assets - operating, net | 162,163 | 127,024 | ||||||
| Right-of-use assets - finance, net | 30,645 | 40,671 | ||||||
| Goodwill | 94,108 | 94,108 | ||||||
| Deposits and other assets | 7,210 | 6,229 | ||||||
| TOTAL ASSETS | $ | 1,421,201 | $ | 1,459,855 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Liabilities | ||||||||
| Current | ||||||||
| Trade payables | 34,557 | 24,786 | ||||||
| Accrued liabilities | 29,450 | 40,918 | ||||||
| Lease liabilities - operating - current portion | 11,517 | 9,776 | ||||||
| Lease liabilities - finance - current portion | 6,464 | 9,789 | ||||||
| Income tax payable | 5,449 | 90,074 | ||||||
| Debts payable - current portion | 19,621 | 23,152 | ||||||
| Accrued interest payable - current portion | 10,891 | 1,983 | ||||||
| Total Current Liabilities | 117,949 | 200,478 | ||||||
| Non-current | ||||||||
| Deferred tax liabilities, net | 64,965 | 64,965 | ||||||
| Uncertain tax position liabilities | 117,644 | - | ||||||
| Lease liabilities - operating - non-current portion | 164,984 | 125,739 | ||||||
| Lease liabilities - finance - non-current portion | 15,136 | 18,007 | ||||||
| Construction finance liabilities | - | 38,205 | ||||||
| Long-term debts payable, net | 386,154 | 411,306 | ||||||
| Accrued interest payable - non-current portion | 5,632 | 5,530 | ||||||
| Other long-term liabilities | 21,968 | 24,973 | ||||||
| TOTAL LIABILITIES | 894,432 | 889,203 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders' equity | ||||||||
| Multiple Voting Shares - no par value, unlimited authorized. Issued and outstanding - nil and 3,696,486 shares, respectively | - | - | ||||||
| Subordinate, Restricted, and Limited Voting Shares - no par value, unlimited authorized. Issued and outstanding - 106,806,135 and 64,574,077 shares, respectively | - | - | ||||||
| Exchangeable Shares: no par value, unlimited authorized. Issued and outstanding - 9,379,224 and 9,645,016 shares, respectively | - | - | ||||||
| Additional paid-in capital | 1,516,384 | 1,370,600 | ||||||
| Treasury stock - nil and 645,300 shares, respectively | - | (8,987 | ) | |||||
| Accumulated other comprehensive income | 3,266 | 3,266 | ||||||
| Accumulated deficit | (978,560 | ) | (783,101 | ) | ||||
| Equity of Ayr Wellness Inc. | 541,090 | 581,778 | ||||||
| Noncontrolling interest | (14,321 | ) | (11,126 | ) | ||||
| TOTAL SHAREHOLDERS' EQUITY | 526,769 | 570,652 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 1,421,201 | $ | 1,459,855 | ||||
| Ayr Wellness Inc. Unaudited Interim Condensed Consolidated Statements of Operations (Expressed in United States Dollars, in thousands, except per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | ||||||||||||
| Revenues, net of discounts | $ | 114,328 | $ | 114,392 | $ | 349,676 | $ | 348,795 | |||||||
| Cost of goods sold | 71,316 | 66,261 | 208,843 | 195,735 | |||||||||||
| Gross profit | 43,012 | 48,131 | 140,833 | 153,060 | |||||||||||
| Operating expenses | |||||||||||||||
| Selling, general, and administrative | 45,004 | 38,833 | 126,014 | 137,813 | |||||||||||
| Impairment of assets | 2,150 | - | 2,150 | - | |||||||||||
| Depreciation and amortization | 12,032 | 11,909 | 36,117 | 39,390 | |||||||||||
| Acquisition and transaction costs | 1,270 | (1,182 | ) | 3,634 | 3,460 | ||||||||||
| Total operating expenses | 60,456 | 49,560 | 167,915 | 180,663 | |||||||||||
| Loss from continuing operations | (17,444 | ) | (1,429 | ) | (27,082 | ) | (27,603 | ) | |||||||
| Other income (expense), net | |||||||||||||||
| Fair value gain on financial liabilities | - | - | - | 23,731 | |||||||||||
| Loss on the extinguishment of debt | - | - | (79,172 | ) | - | ||||||||||
| Gain (loss) on sale of assets | 108 | (22 | ) | 2,936 | (66 | ) | |||||||||
| Interest expense, net | (20,245 | ) | (10,772 | ) | (58,192 | ) | (28,834 | ) | |||||||
| Interest income | 58 | 193 | 253 | 591 | |||||||||||
| Other income, net | 123 | 6,303 | 2,527 | 6,934 | |||||||||||
| Total other (expense) income, net | (19,956 | ) | (4,298 | ) | (131,648 | ) | 2,356 | ||||||||
| Loss from continuing operations before income taxes and noncontrolling interest | (37,400 | ) | (5,727 | ) | (158,730 | ) | (25,247 | ) | |||||||
| Income taxes | |||||||||||||||
| Current tax provision | (13,113 | ) | (13,543 | ) | (39,425 | ) | (37,608 | ) | |||||||
| Total income taxes | (13,113 | ) | (13,543 | ) | (39,425 | ) | (37,608 | ) | |||||||
| Net loss from continuing operations | (50,513 | ) | (19,270 | ) | (198,155 | ) | (62,855 | ) | |||||||
| Discontinued operations | |||||||||||||||
| Loss from discontinued operations, net of taxes (including loss on disposal of | - | (996 | ) | - | (185,683 | ) | |||||||||
| Income (loss) from discontinued operations | - | (996 | ) | - | (185,683 | ) | |||||||||
| Net loss | (50,513 | ) | (20,266 | ) | (198,155 | ) | (248,538 | ) | |||||||
| Net income (loss) attributable to noncontrolling interest | 113 | (1,020 | ) | (2,696 | ) | (4,756 | ) | ||||||||
| Net loss attributable to Ayr Wellness Inc. | $ | (50,626 | ) | $ | (19,246 | ) | $ | (195,459 | ) | $ | (243,782 | ) | |||
| Basic and diluted net loss per share | |||||||||||||||
| Continuing operations | $ | (0.44 | ) | $ | (0.24 | ) | $ | (1.79 | ) | $ | (0.79 | ) | |||
| Discontinued operations | - | (0.01 | ) | - | (2.54 | ) | |||||||||
| Total (basic and diluted) net loss per share | $ | (0.44 | ) | $ | (0.25 | ) | $ | (1.79 | ) | $ | (3.33 | ) | |||
| Weighted average number of shares outstanding (basic and diluted) | 114,839 | 76,563 | 108,976 | 73,105 | |||||||||||
| Ayr Wellness Inc. Unaudited Interim Condensed Consolidated Statements of Cash Flows (Expressed in United States Dollars, in thousands) | ||||||
| Nine Months Ended | ||||||
| September 30, 2024 | September 30, 2023 | |||||
| Operating activities | ||||||
| Consolidated net loss | (198,155 | ) | $ | (248,538 | ) | |
| Less: Loss from discontinued operations | - | (4,492 | ) | |||
| Net loss from continuing operations before noncontrolling interest | (198,155 | ) | (244,046 | ) | ||
| Adjustments for: | ||||||
| Fair value gain on financial liabilities | - | (23,731 | ) | |||
| Stock-based compensation | 15,696 | 13,338 | ||||
| Shares issued for consulting services | - | 79 | ||||
| Depreciation and amortization | 21,180 | 24,984 | ||||
| Amortization of intangible assets | 43,828 | 43,828 | ||||
| Amortization of financing costs | 15,270 | 1,743 | ||||
| Amortization of financing discount | 5,597 | - | ||||
| Amortization of financing premium | (52 | ) | (2,263 | ) | ||
| Provision for credit losses | 528 | - | ||||
| Employee retention credits recorded in other income | (318 | ) | (5,238 | ) | ||
| Impairment of assets | 2,150 | |||||
| (Gain) loss on sale of assets | (2,936 | ) | 66 | |||
| Loss on the extinguishment of debt | 79,172 | - | ||||
| Loss on the disposal of Arizona business | - | 181,191 | ||||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable | 1,389 | (2,305 | ) | |||
| Inventory | (13,189 | ) | 1,626 | |||
| Prepaid expenses, deposits, and other current assets | 6,035 | (4,164 | ) | |||
| Trade payables | 2,113 | (5,334 | ) | |||
| Accrued liabilities | (5,017 | ) | 3,245 | |||
| Accrued interest payable, current and non-current portions | 9,010 | 6,653 | ||||
| Lease liabilities - operating | 3,673 | 1,857 | ||||
| Income tax payable | (84,625 | ) | 31,396 | |||
| Uncertain tax position liabilities | 117,644 | - | ||||
| Cash provided by continuing operations | 18,993 | 22,925 | ||||
| Cash provided by discontinued operations | - | 2,180 | ||||
| Cash provided by operating activities | 18,993 | 25,105 | ||||
| Investing activities | ||||||
| Purchase of property, plant, and equipment | (16,491 | ) | (20,790 | ) | ||
| Capitalized interest | (4,766 | ) | (7,274 | ) | ||
| Proceeds from the sale of assets | 316 | - | ||||
| Cash paid for business combinations and asset acquisitions, net of cash acquired | - | (1,500 | ) | |||
| Cash paid for business combinations and asset acquisitions, working capital | - | (2,600 | ) | |||
| Cash paid for bridge financing | - | (72 | ) | |||
| Purchase of intangible asset | (213 | ) | (1,700 | ) | ||
| Cash used in investing activities from continuing operations | (21,154 | ) | (33,936 | ) | ||
| Proceeds from sale of Arizona business - discontinued operation | - | 18,084 | ||||
| Cash received for working capital - discontinued operations | - | 840 | ||||
| Cash used in investing activities of discontinued operations | - | (44 | ) | |||
| Cash used in investing activities | (21,154 | ) | (15,056 | ) | ||
| Financing activities | ||||||
| Proceeds from exercise of warrants | 27 | - | ||||
| Proceeds from notes payable | 40,000 | 10,430 | ||||
| Proceeds from financing transaction, net of financing costs | 8,309 | 39,100 | ||||
| Debt issuance costs paid | (9,216 | ) | - | |||
| Payment for settlement of contingent consideration | (10,094 | ) | (10,118 | ) | ||
| Tax withholding on stock-based compensation awards | (283 | ) | (360 | ) | ||
| Repayments of debts payable | (19,181 | ) | (49,098 | ) | ||
| Repayments of lease liabilities - finance (principal portion) | (7,589 | ) | (7,676 | ) | ||
| Cash provided by (used in) financing activities by continuing operations | 1,973 | (17,722 | ) | |||
| Cash used in financing activities from discontinued operations | - | (124 | ) | |||
| Cash provided by (used in) financing activities | 1,973 | (17,846 | ) | |||
| Net decrease in cash and cash equivalents and restricted cash | (188 | ) | (7,797 | ) | ||
| Cash, cash equivalents and restricted cash at beginning of the period | 50,766 | 76,827 | ||||
| Cash included in assets held-for-sale | - | 3,813 | ||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 50,578 | $ | 72,843 | ||
| Supplemental disclosure of cash flow information: | ||||||
| Interest paid during the period, net | $ | 34,178 | $ | 25,430 | ||
| Income taxes paid during the period, net | 6,405 | 7,080 | ||||
| Non-cash investing and financing activities: | ||||||
| Recognition of right-of-use assets for operating leases | 48,537 | 8,586 | ||||
| Recognition of right-of-use assets for finance leases | 2,440 | 4,402 | ||||
| Issuance of promissory note related to business combinations | 1,820 | 1,580 | ||||
| Conversion of convertible note related to business combination | 700 | 2,800 | ||||
| Issuance of Equity Shares related to business combinations and asset acquisitions | 210 | 115 | ||||
| Issuance of Equity Shares related to settlement of contingent consideration | - | 4,647 | ||||
| Issuance of promissory note related to settlement of contingent consideration | - | 14,000 | ||||
| Settlement of contingent consideration | - | 37,713 | ||||
| Capital expenditure for cultivation facility | 2,467 | 1,764 | ||||
| Extinguishment of construction finance liabilities for lease reclassification of cultivation facility | 39,176 | - | ||||
| Extinguishment of note payable related to sale of Arizona business | - | 22,505 | ||||
| Extinguishment of accrued interest payable related to sale of Arizona business | - | 1,165 | ||||
| Reduction of lease liabilities related to sale of Arizona business | - | 16,734 | ||||
| Reduction of right-of-use assets related to sale of Arizona business | - | 16,739 | ||||
| Reclassification of right-of-use assets to property, plant, and equipment due to exercise of repurchase option at lease expiration | 5,597 | - | ||||
| Retirement of Treasury Shares | 8,987 | - | ||||
| Issuance of warrants in connection with debt extinguishment | 47,049 | - | ||||
| Issuance of Equity Shares in connection with debt extinguishment | 94,302 | - | ||||
| Ayr Wellness Inc. Unaudited Interim Consolidated Adjusted EBITDA and Gross Profit Reconciliation (Expressed in United States Dollars, in thousands) | ||||||||||
| Three Months Ended | Nine Months Ended | |||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||
| $ | $ | $ | $ | |||||||
| Loss from continuing operations (GAAP) | (17,444 | ) | (1,429 | ) | (27,082 | ) | (27,603 | ) | ||
| Interest (within cost of goods sold "COGS") | 575 | 776 | 1,869 | 2,290 | ||||||
| Depreciation and amortization (from statement of cash flows) | 21,151 | 22,019 | 65,008 | 68,812 | ||||||
| Acquisition and transaction costs | 1,270 | (1,182 | ) | 3,634 | 3,460 | |||||
| Stock-based compensation, non-cash | 8,794 | 3,410 | 15,696 | 13,417 | ||||||
| Impairment of assets | 2,150 | - | 2,150 | - | ||||||
| Start-up costs1 | 4,762 | 2,909 | 10,638 | 8,871 | ||||||
| Other2 | 4,888 | 1,924 | 9,024 | 14,961 | ||||||
| 43,590 | 29,856 | 108,019 | 111,811 | |||||||
| Adjusted EBITDA from continuing operations (non-GAAP) | 26,146 | 28,427 | 80,937 | 84,208 | ||||||
| 1 These are set-up costs to prepare a location for its intended use. Start-up costs are expensed as incurred and are not indicative of ongoing operations | ||||||||||
| 2 Other non-core costs including non-operating adjustments, severance costs and non-cash inventory write-downs | ||||||||||
| Three Months Ended | Nine Months Ended | |||||||||
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||
| $ | $ | $ | $ | |||||||
| Gross profit (GAAP) | 43,012 | 48,131 | 140,833 | 153,060 | ||||||
| Interest (within COGS) | 575 | 776 | 1,869 | 2,290 | ||||||
| Depreciation and amortization (within COGS) | 9,119 | 10,109 | 28,892 | 29,422 | ||||||
| Start-up costs (within COGS) | 3,102 | 1,295 | 6,258 | 4,305 | ||||||
| Other (within COGS) | 4,567 | 196 | 5,886 | 5,773 | ||||||
| Adjusted Gross Profit from continuing operations (non-GAAP) | 60,375 | 60,507 | 183,738 | 194,850 | ||||||
FAQ
What was AYR Wellness (AYRWF) revenue in Q3 2024?
What is AYR Wellness (AYRWF) Q4 2024 guidance?
How many retail stores does AYR Wellness (AYRWF) operate as of Q3 2024?
What was AYR Wellness (AYRWF) Adjusted EBITDA in Q3 2024?
